Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-023448
Filing Date
2025-05-08
Accepted
2025-05-08 07:06:13
Documents
85
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20250331.htm   iXBRL 10-Q 962589
2 EX-10.1 vnda3312025ex101.htm EX-10.1 30615
3 EX-31.1 vndaex311331202510q.htm EX-31.1 10477
4 EX-31.2 vndaex312331202510q.htm EX-31.2 10101
5 EX-32.1 vndaex321331202510q.htm EX-32.1 6660
  Complete submission text file 0001628280-25-023448.txt   6099212

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20250331.xsd EX-101.SCH 49552
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20250331_cal.xml EX-101.CAL 69146
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20250331_def.xml EX-101.DEF 225164
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20250331_lab.xml EX-101.LAB 577024
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20250331_pre.xml EX-101.PRE 424895
88 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20250331_htm.xml XML 721878
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 25923819
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)